New Data on Bristol-Myers Squibb Oncology Compounds to Be Featured in More Than 100 Abstracts at ASCO 2008PRINCETON, N.J.--(BUSINESS WIRE)--May 15, 2008 - More than 100 scientific abstracts on six Bristol-Myers Squibb Company (NYSE:BMY) oncology compounds will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30- June 2.
Data will be presented on ERBITUX(R) (cetuximab), SPRYCEL(R) (dasatinib), IXEMPRA(R) (ixabepilone) and investigational compounds ipilimumab, brivanib and CT-322. Studies focus on a broad spectrum of cancer types, including colorectal, head and neck, leukemia, lung, breast, melanoma and prostate.
"As cancer therapy evolves, so does Bristol-Myers Squibb's innovation in finding new ways to address significant unmet medical needs," said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, Research and Development, Bristol-Myers Squibb. "The data being presented at this year's ASCO annual meeting reflect the broader potential of our medicines as we explore new ways to help fight cancer. Our robust oncology pipeline holds the promise and potential of delivering additional treatment options for physicians and patients."
Bristol-Myers Squibb, and its partners ImClone Systems, Inc. and Merck KGaA, plan to present new data on ERBITUX, including two studies that will be featured in ASCO plenary sessions and an ASCO press briefing on Sunday, June 1. The companies are investigating the potential of ERBITUX in non-small cell lung cancer and data from a large, completed phase III trial in this tumor type will be presented for the first time at ASCO. Also to be presented are retrospective analyses assessing the link between patients' KRAS gene status of the individual's tumor and the treatment effect with ERBITUX. Both trials have been planned and conducted by Merck KGaA, Darmstadt, Germany.
Data on SPRYCEL will be featured in two studies of patients with chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia (Ph+ALL) with up to two years of follow-up. For the first time, Phase 2 data will be presented on the potential of SPRYCEL in prostate cancer. The company is actively investigating the potential of SPRYCEL in other solid tumor types, including glioblastoma, breast cancer and colorectal cancer.
IXEMPRA will be highlighted in abstracts evaluating combination regimens with other chemotherapies or targeted agents, as well as in additional tumor types.
Bristol-Myers Squibb and its partner Medarex will present data on the investigational immunotherapy ipilimumab. New Phase 2 ipilimumab data will evaluate the medicine's potential in patients with metastatic melanoma.
New data on Bristol-Myers Squibb compounds, brivanib and CT-322, will also be presented at ASCO. CT-322 was discovered by Adnexus Therapeutics, which was acquired by Bristol-Myers Squibb in October 2007. CT-322 is being evaluated for use in the treatment of glioblastoma, a type of brain cancer, and will be featured in an oral presentation at ASCO. Brivanib is being investigated for use in colorectal and other cancers.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life.
Full prescribing information for ERBITUX, SPRYCEL and IXEMPRA is available at http://www.bms.com/.
Posted: May 2008